Case-Control Study of Pesticides and Childhood Leukemia
NCT ID: NCT00342888
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
629 participants
OBSERVATIONAL
2001-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Childhood Leukemia Cases
Cases were diagnosed at 9 hospitals in Northern California
No interventions assigned to this group
Matched Controls
Controls were matched on age, gender and race/ethnicity from birth certificates in Northern California
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Study population is limited to children.
All races and ethnicities will be included in the study.
Tier I:
The cases eligible for participation in Tier I of the UCB study of all newly diagnosed cases of childhood leukemia 0-14 years old resident in 35 counties in San Francisco Bay Area and the Central Valley
Tier II:
Tier II participants will be selected from cases and controls that complete the Tier I interview. Cases (and their match controls), aged 0-7, diagnosed from December 1, 1999 through 2003, and who still reside at the home where they were living ate the diagnosis date, will be eligible for the Tier II interview.
8 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rena R Jones, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Berkeley
Berkeley, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Metayer C, Colt JS, Buffler PA, Reed HD, Selvin S, Crouse V, Ward MH. Exposure to herbicides in house dust and risk of childhood acute lymphoblastic leukemia. J Expo Sci Environ Epidemiol. 2013 Jul;23(4):363-70. doi: 10.1038/jes.2012.115. Epub 2013 Jan 16.
Deziel NC, Rull RP, Colt JS, Reynolds P, Whitehead TP, Gunier RB, Month SR, Taggart DR, Buffler P, Ward MH, Metayer C. Polycyclic aromatic hydrocarbons in residential dust and risk of childhood acute lymphoblastic leukemia. Environ Res. 2014 Aug;133:388-95. doi: 10.1016/j.envres.2014.04.033. Epub 2014 Jun 17.
Ward MH, Colt JS, Metayer C, Gunier RB, Lubin J, Crouse V, Nishioka MG, Reynolds P, Buffler PA. Residential exposure to polychlorinated biphenyls and organochlorine pesticides and risk of childhood leukemia. Environ Health Perspect. 2009 Jun;117(6):1007-13. doi: 10.1289/ehp.0900583. Epub 2009 Jan 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02-C-N030
Identifier Type: -
Identifier Source: secondary_id
999902030
Identifier Type: -
Identifier Source: org_study_id
NCT00556985
Identifier Type: -
Identifier Source: nct_alias